Summary & Overview
HCPCS J0202: Alemtuzumab Injection, 1 mg
HCPCS Level II code J0202 denotes a 1 mg unit of alemtuzumab delivered by injection or infusion. Alemtuzumab is a monoclonal antibody used in specialty care settings; accurate coding of its administration is important for claims processing and national tracking of high-cost biologic therapies. This code matters nationally because it captures use of a specialty oncology/autoimmune agent across hospital outpatient departments, infusion centers, and specialty clinics.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for alemtuzumab administration, typical service settings, and the payer landscape relevant to this HCPCS Level II code. The publication summarizes available benchmarks and policy-relevant items, highlights coding and billing considerations tied to HCPCS reporting, and outlines where to look for related coverage policy updates and reimbursement guidance. Where specific input fields were not provided, the publication notes that data is not available in the input and focuses on standard clinical and billing interpretations for national audiences.
Billing Code Overview
HCPCS Level II code J0202 represents an injection of alemtuzumab supplied in a unit of 1 mg. This code is used to report administration of the monoclonal antibody agent alemtuzumab for therapeutic purposes.
-
Service type: Drug administration (intravenous infusion or injection) delivered as a physician- or facility-administered medication
-
Typical site of service: Hospital outpatient department, ambulatory infusion center, oncology or specialty clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45–60 year-old adult with relapsing-remitting multiple sclerosis or other approved hematologic/autoimmune indications receiving alemtuzumab as an intravenous infusion in an ambulatory infusion center or hospital outpatient department. The drug is supplied and billed as J0202 per 1 mg vial; dosing protocols often require weight-based total doses administered over consecutive days during a single treatment course (for example, 12 mg/day given as multiple vials diluted and infused). The clinical workflow includes pre-infusion assessment (vital signs, laboratory review including CBC, renal and hepatic function, and infection screening), verification of informed consent and REMS requirements, pharmacy preparation and compounding of the required number of J0202 vials, administration by an infusion nurse under physician or advanced practice clinician supervision, monitoring for infusion reactions during and for several hours after infusion, and documentation of total milligrams administered and lot numbers. Typical sites of service are an ambulatory infusion center, physician office with infusion capabilities, or an outpatient hospital infusion unit. Documentation must include indication, total milligrams administered, infusion start and stop times, pre- and post-vital signs, and any use of concomitant medications for infusion reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |